Angiex Secures $31M to Advance Novel Nuclear-Delivered Cancer Therapy

NEW YORK, NY – November 17, 2025 – Angiex Inc., a privately held biotechnology company, announced the successful completion of a $31 million financing round to fuel the Phase 1 clinical trial of AGX101, its lead product. This novel therapy utilizes a unique approach – a Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) – aimed at improving drug delivery directly into the nucleus of cancer cells and disrupting tumor blood supply.

Pioneering a New Approach to Targeted Cancer Therapy

AGX101 represents a departure from traditional Antibody-Drug Conjugates (ADCs). While conventional ADCs deliver cytotoxic payloads to cancer cells, AGX101 is specifically engineered to bypass cellular barriers and deliver its payload directly into the nucleus, where it can more effectively disrupt cancer cell function. “The beauty of this technology is the precision,” explained one industry analyst. “By getting the drug directly into the nucleus, they hope to overcome some of the resistance mechanisms that develop with conventional therapies and maximize efficacy.”

The therapy targets TM4SF1, a protein highly expressed in a wide range of solid tumors and tumor vasculature. High expression of this protein is linked to more aggressive tumors and poorer patient outcomes, making it a promising target for cancer therapy. Angiex's ND-ADC platform allows it to deliver a powerful cytotoxic payload directly to cells expressing TM4SF1, both in the tumor itself and in the blood vessels that feed it.

“This dual action – disrupting blood supply and directly killing cancer cells – could be a game-changer,” said a researcher familiar with the company’s work. “It’s a very elegant approach to tackling the complexities of solid tumors.”

Investor Confidence and the Promise of Nuclear Delivery

The $31 million financing round involved a mix of new and existing investors, with Paulson Investment Company acting as the placement agent for a $16 million equity offering. This level of investment signals strong confidence in Angiex's technology and the potential of its ND-ADC platform.

“Investors are always looking for innovative approaches to cancer treatment,” said an investment banker specializing in biotechnology. “Angiex’s focus on nuclear delivery is particularly appealing because it addresses a key challenge in the field – getting the drug where it needs to go.”

The funds will be used to advance the Phase 1 clinical trial, which is currently recruiting patients with advanced solid tumors. The trial will assess the safety, tolerability, and preliminary clinical activity of AGX101. Initial results are expected in late 2025 or early 2026. Angiex is also collaborating with Abzena, an integrated CDMO, for the development and manufacture of clinical trial material.

The Competitive Landscape and the Future of Targeted Therapies

The ADC market is already crowded, with numerous companies developing targeted therapies for cancer. However, Angiex differentiates itself through its unique ND-ADC technology and its focus on nuclear delivery. While several firms are exploring different ADC strategies, few are tackling the challenge of directly accessing the cancer cell nucleus.

“It’s a high-risk, high-reward approach,” said a pharmaceutical analyst. “If they can prove that nuclear delivery improves efficacy and reduces side effects, it could open up a whole new avenue for cancer treatment.”

The company's founders, experts in angiogenesis and oncology, bring a wealth of experience to the project. Their deep understanding of tumor biology and drug delivery is crucial for the success of AGX101. Angiex also boasts a lean, focused team dedicated to advancing its innovative platform.

While challenges remain in bringing AGX101 to market, the company's novel approach and strong investor support position it as a promising player in the rapidly evolving field of targeted cancer therapies. The company anticipates expanding its ND-ADC platform to develop treatments for additional cancer types and potentially other diseases in the future.